New nasal spray could prevent migraines without drugs
NCT ID NCT07100496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a nasal spray called MIG-SPRAY for preventing migraines in 45 adults aged 18-55. The spray forms a protective film inside the nose to possibly stop migraine triggers. Participants use it three times daily for three months, and researchers track side effects and migraine frequency compared to a control group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MIG-SPRAY (a film-forming liquid nasal spray, classified as a medical device)
- What this could lead to
- If it works, this could offer a new, non-drug option for preventing migraines with fewer side effects.
- What could go wrong
- This is a small, early-phase trial focused on safety, not effectiveness. The device may not reduce migraines significantly, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Clermont-ferrand
Clermont-Ferrand, 63000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?